Targeting inflammasome/IL-1 pathways for cancer immunotherapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Guo, Beichu ^a,b   Fu, Shunjun ^a   Zhang, Jinyu ^a   Liu, Bei ^a,b   Li, Zihai ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NLRP3 PROTEIN, MOUSE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR;

AGONISTS; ANIMAL; BREAST TUMOR; C57BL MOUSE; CYTOLOGY; DEFICIENCY; DISEASE MODEL; FEMALE; GENETICS; HUMAN; IMMUNOTHERAPY; KNOCKOUT MOUSE; LUNG TUMOR; MACROPHAGE; METABOLISM; MORTALITY; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CASPASE 1; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; INFLAMMASOMES; INTERLEUKIN-1BETA; LUNG NEOPLASMS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MYELOID-DERIVED SUPPRESSOR CELLS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; NLR PROTEINS; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION;

EID: 84993950797     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36107     Document Type: Article

References (69)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51 (2010).
3. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252 (2009).
4. McAllister, S. S. & Weinberg, R. A. Tumor-host interactions: a far-reaching relationship. J Clin Oncol 28, 4022-4028 (2010).
5. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
6. Sharma, D. & Kanneganti, T. D. The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation. J Cell Biol 213, 617-629 (2016).
7. Rathinam, V. A. & Fitzgerald, K. A. Inflammasome Complexes: Emerging Mechanisms and Effector Functions. Cell 165, 792-800 (2016).
8. Lukens, J. R. & Kanneganti, T. D. Beyond canonical inflammasomes: emerging pathways in IL-1-mediated autoinflammatory disease. Semin Immunopathol (2014).
9. Lamkanfi, M. & Dixit, V. M. Mechanisms and Functions of Inflammasomes. Cell 157, 1013-1022 (2014).
10. Wen, H., Ting, J. P. & O'Neill, L. A. A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol 13, 352-357 (2012).
11. Broz, P. & Monack, D. M. Molecular mechanisms of inflammasome activation during microbial infections. Immunol Rev 243, 174-190 (2011).
12. Guo, B. & Li, Z. Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases. Front Genet 5, 242 (2014).
13. Ting, J. P., Duncan, J. A. & Lei, Y. How the noninflammasome NLRs function in the innate immune system. Science 327, 286-290 (2010).
14. Gross, O. et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36, 388-400 (2012).
15. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15, 1170-1178 (2009).
16. Cassel, S. L., Joly, S. & Sutterwala, F. S. The NLRP3 inflammasome: a sensor of immune danger signals. Semin Immunol 21, 194-198 (2009).
17. Zhang, J., Fu, S., Sun, S., Li, Z. & Guo, B. Inflammasome activation has an important role in the development of spontaneous colitis. Mucosal Immunol (2014).
18. Bryant, C. & Fitzgerald, K. A. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 19, 455-464 (2009).
19. Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1 (IL-1) pathway. Sci Signal 3, cm1 (2010).
20. Jin, L. et al. Expression of interleukin-1beta in human breast carcinoma. Cancer 80, 421-434 (1997).
21. Pantschenko, A. G. et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 23, 269-284 (2003).
22. Perrier, S., Caldefie-Chezet, F. & Vasson, M. P. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett 583, 259-265 (2009).
23. Valdivia-Silva, J. E. et al. Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Lett 283, 176-185 (2009).
24. Allen, I. C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207, 1045-1056 (2010).
25. Allam, R. et al. Epithelial NAIPs protect against colonic tumorigenesis. J Exp Med 212, 369-383 (2015).
26. Dupaul-Chicoine, J. et al. The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity. Immunity 43, 751-763 (2015).
27. Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 107, 21635-21640 (2010).
28. Man, S. M. et al. Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer. Cell 162, 45-58 (2015).
29. Davis, B. K., Wen, H. & Ting, J. P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29, 707-735 (2011).
30. Bruchard, M. et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19, 57-64 (2013).
31. Zitvogel, L., Kepp, O., Galluzzi, L. & Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13, 343-351 (2012).
32. van de Veerdonk, F. L., Netea, M. G., Dinarello, C. A. & Joosten, L. A. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 32, 110-116 (2011).
33. Ichinohe, T., Lee, H. K., Ogura, Y., Flavell, R. & Iwasaki, A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 206, 79-87 (2009).
34. Kim, B. H. et al. Interferon-induced guanylate-binding proteins in inflammasome activation and host defense. Nat Immunol 17, 481-489 (2016).
35. Cai, S., Batra, S., Wakamatsu, N., Pacher, P. & Jeyaseelan, S. NLRC4 inflammasome-mediated production of IL-1beta modulates mucosal immunity in the lung against gram-negative bacterial infection. J Immunol 188, 5623-5635 (2012).
36. Crusz, S. M. & Balkwill, F. R. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12, 584-596 (2015).
37. Pollard, J. W. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84, 623-630 (2008).
38. Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70, 5728-5739 (2010).
39. Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22, 231-237 (2010).
40. Mantovani, A. The growing diversity and spectrum of action of myeloid-derived suppressor cells. Eur J Immunol 40, 3317-3320 (2010).
41. Torroella-Kouri, M., et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res 69, 4800-4809 (2009).
42. Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellsuppressive activity. Blood 111, 4233-4244 (2008).
43. Stearman, R. S., Dwyer-Nield, L., Grady, M. C., Malkinson, A. M. & Geraci, M. W. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res 68, 34-43 (2008).
44. Zheng, Y. et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114, 3625-3628 (2009).
45. Donkor, M. K. et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 9, 937-948 (2009).
46. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59, 1593-1600 (2010).
47. Sica, A. Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol 32, 153-158 (2010).
48. Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163, 2113-2126 (2003).
49. Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954-961 (1992).
50. Chen, G. Y., Liu, M., Wang, F., Bertin, J. & Nunez, G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 186, 7187-7194 (2011).
51. Allen, I. C. et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NFkappaB signaling. Immunity 36, 742-754 (2012).
52. Drexler, S. K. et al. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci USA 109, 18384-18389 (2012).
53. Okamoto, M. et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 285, 6477-6488 (2010).
54. Liu, W. et al. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol 133, 518-527 (2013).
55. van Deventer, H. W. et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res 70, 10161-10169 (2010).
56. Kadariya, Y. et al. Inflammation-Related IL1beta/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. Cancer Prev Res (Phila) 9, 406-414 (2016).
57. Westbom, C. et al. Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma. PLoS One 10, e0145404 (2015).
58. Bersudsky, M. et al. Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut 63, 598-609 (2014).
59. Song, X. et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 171, 6448-6456 (2003).
60. Hembruff, S. L. & Cheng, N. Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther 7, 254-267 (2009).
61. Mantovani, A. et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21, 27-39 (2010).
62. Balkwill, F. R. The chemokine system and cancer. J Pathol 226, 148-157 (2012).
63. Gorbachev, A. V. & Fairchild, R. L. Regulation of chemokine expression in the tumor microenvironment. Crit Rev Immunol 34, 103-120 (2014).
64. Barton, G. M. & Medzhitov, R. Toll-like receptor signaling pathways. Science 300, 1524-1525 (2003).
65. Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650 (2011).
66. Svensson, S. et al. CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer. Clin Cancer Res 21, 3794-3805 (2015).
67. Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N. & Muschel, R. J. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7, 28697-28710 (2016).
68. Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225 (2011).
69. Guo, B., Chang, E. Y. & Cheng, G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 118, 1680-1690 (2008).